Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich) Switzerland
Dario Neri studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry at the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich. He then performed post-doctoral research at the Medical Research Council Centre in Cambridge (UK), under the supervision of Sir Gregory Winter. He has now been a Professor at the ETH Zürich since 1996.
Advances in technologies for the construction and screening of large combinatorial libraries of proteins (e.g., antibody phage display libraries) or of small organic ligands (e.g., DNA-encoded chemical libraries) have facilitated the isolation of specific binders against protein targets of pharmaceutical interest.
In this lecture, I will show examples of how my lab (in collaboration with Philogen; www.philogen.com) has used antibodies or small organic ligands, isolated from large combinatorial libraries, for the design of new pharmaceutical agents, capable of selective localization at the site of disease.
In particular, I will present how (i) antibody-cytokine fusion proteins can be potently active in preclinical models of disease and in clinical trials, and how (ii) small molecule-drug conjugates outperform antibody-drug conjugates for cancer therapy applications
Host: Kristian Sandberg (email@example.com)
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.